Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda seeks resolution to transfer pricing dispute

This article was originally published in Scrip

Executive Summary

Takedais pursuing a new mutual agreement procedure under US/Japan tax agreements in the hope of settling a payment of ¥57.1 billion ($530.7 million) which it was ordered to make by Japanese tax authorities in June 2006. This followed an official assessment of profits earned in the US over six years from the end of March 2000 under agreements between Takeda and its now-dissolved US joint venture withAbbott, TAP Pharmaceutical Products, for the proton pump inhibitor Prevacid (lansoprazole). Takeda paid the additional taxes in July 2006 but lodged an appeal on which no decision has yet been made. This will now be withdrawn, with the firm to seek a new resolution under a mutual advance pricing agreement which it is seeking for the period from April 2005.

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 

PMDA Eyes More Japan-First Approvals In Access Push

Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel